CLINICAL_TRIALS
trial_result
· 2024-04-18
Clinical Trial Update: Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients [Phase 2]
Summary
Phase 2 trial update on CTL019 (tisagenlecleucel) for adult diffuse large B-cell lymphoma; results posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Status: COMPLETED | Results posted: 2024-04-18